Natera CEO Steven Chapman sells $526k in common stock

Steven Leonard Chapman, CEO and President of Natera, Inc. (NASDAQ:NTRA), disposed of common stock totaling approximately $526,143 on October 1, 2026.

According to a recent filing, Mr. Chapman sold 1,273 shares of Natera common stock at a price of $413.31 per share. Following this transaction, Mr. Chapman beneficially owns 96,926 shares of the company’s common stock. The sale comes as Natera’s stock trades near its 52-week high of $427.47, with shares delivering a remarkable 145% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. The sale was executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Chapman on December 11, 2023, and subsequently amended on December 2, 2024, and March 5, 2026. For deeper insights into Natera’s valuation and performance, InvestingPro offers a comprehensive Pro Research Report with expert analysis and additional ProTips for subscribers.

In other recent news, Natera reported second-quarter revenue that significantly surpassed Wall Street expectations, reaching approximately $753 million compared to the forecast of $661.26 million. The company also raised its full-year revenue guidance and highlighted record test volumes, improved margins, and several regulatory victories. RBC Capital has increased its price target for Natera to $460, maintaining an Outperform rating, due to the company’s promising growth prospects in minimal residual disease (MRD) testing, a market where Natera holds a strong position. Additionally, Rothschild Redburn has initiated coverage on Natera with a Buy rating and set a price target of $385, emphasizing Natera’s leadership in MRD testing. The firm noted the company’s Signatera tumor-informed test and its development of a multi-cancer early detection screening test. These developments reflect Natera’s ongoing expansion and strategic positioning in the MRD testing market.